Articles from Resilience

Collaboration helps security and risk leaders communicate effectiveness of security investments and may help improve cyber insurance coverage terms

National Resilience (“Resilience”), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today provided an update on its CDMO business strategy and financing in a letter to its customers.

Industry veteran and former CrowdStrike sales leader to boost revenue streams and meet growing demand for the Resilience Solution

Ransomware attacks surge in frequency and severity since 2023, buoyed by major attacks on Change Healthcare, CDK Global, and others

SAN FRANCISCO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Resilience, a next generation cyber risk solutions company, announced today that it has achieved the Amazon Web Services (AWS) Cyber Insurance Competency. This specialization recognizes Resilience as an AWS Partner that helps AWS customers improve their security posture and find affordable cyber insurance policies through a new, simplified customer experience. 

Big game hunting, attacks on vendors, and data exfiltration rising as threat actors pursue bigger targets

New funding will accelerate adoption of new Resilience Solution and expansion across Europe

Organizations embracing Cyber Resilience more likely to evade extortion payments

Leadership role will focus on supporting new Resilience Solution across global markets

Resilience reinvents the cyber risk market, again

Author Richard Seiersen provides a start-to-finish guide for realistically measuring cybersecurity risk, a core step to building lasting Cyber Resilience

National Resilience, Inc. (Resilience) and AstraZeneca PLC announced today that the companies will establish a long-term biomanufacturing relationship in support of AstraZeneca’s portfolio. Under the agreement, AstraZeneca will have strategic access to Resilience’s end-to-end capabilities. Resilience will purchase AstraZeneca’s manufacturing facility located in West Chester, Ohio and will manufacture select AstraZeneca medicines at the facility as part of a multi-year supply agreement. The companies anticipate completing the transaction in early 2023, subject to receipt of regulatory approvals and the satisfaction of other customary closing conditions. Upon closing, Resilience will acquire the West Chester site’s operations and physical assets, retain the site’s leadership and employees, and continue to invest in the workforce and facility.

Goldman Sachs (NYSE:GS) is recognizing Rahul Singhvi, ScD, Chief Executive Officer of National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, as one of the Most Exceptional Entrepreneurs of 2022 at its Builders and Innovators Summit in Healdsburg, California.

National Resilience, Inc. (Resilience), a manufacturing and technology company, and Harvard University have established a five-year research and development alliance with a $30 million commitment from Resilience directed toward the development of complex medicines, including biologics, vaccines, nucleic acids and cell and gene therapies.

Resilience (National Resilience, Inc.), a company building the world’s most advanced biopharmaceutical manufacturing ecosystem, announced it has acquired Ology Bioservices, Inc., (Ology Bio) a privately held company that also specializes in biologic drug substance manufacturing from early stage through commercial products.